HERC4 (HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase 4) is a member of the HERC family of E3 ubiquitin ligases that play critical roles in protein ubiquitination, cellular signaling, and protein quality control. HERC4 specifically functions as a HECT-type E3 ligase that catalyzes the transfer of ubiquitin to substrate proteins, targeting them for proteasomal degradation or altering their function through monoubiquitination or polyubiquitination. The ubiquitin-proteasome system (UPS) is essential for neuronal protein homeostasis, and dysfunction in this pathway is a hallmark of neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
| Property |
Value |
| Symbol |
HERC4 |
| Full Name |
HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase 4 |
| Chromosomal Location |
10q21.3 |
| NCBI Gene ID |
26091 |
| OMIM |
610215 |
| Ensembl ID |
ENSG00000138641 |
| UniProt ID |
Q8N7R4 |
| Protein Length |
475 amino acids |
| Molecular Weight |
~53 kDa |
¶ Protein Structure and Function
¶ Domain Architecture
HERC4 contains several key structural domains:
N-terminal RLD (RCC1-like Domain): Contains multiple RCC1 (Regulator of Chromosome Condensation 1) homology repeats that function as:
- Protein-protein interaction modules
- Guanine nucleotide exchange factors for some targets
- Scaffolds for complex assembly
C-terminal HECT Domain: The HECT (Homologous to E6AP C-terminus) domain is the catalytic core:
- Contains catalytic cysteine residue (Cys969 in HERC4)
- Forms thioester intermediate with ubiquitin
- Transfers ubiquitin to substrate lysine residues
Linker Region: Connects RLD and HECT domains, may regulate activity
HERC4 catalyzes ubiquitination through a three-step process:
- E1 Activation: Ubiquitin-activating enzyme (E1) activates ubiquitin in an ATP-dependent manner
- E2 Conjugation: Activated ubiquitin is transferred to the E2 conjugating enzyme
- E3 Ligation: HERC4 (E3) recognizes specific substrates and catalyzes ubiquitin transfer to substrate lysine
While specific substrates of HERC4 in neurons are being elucidated, the enzyme is known to regulate:
- Cell cycle proteins
- Apoptotic regulators
- Signaling molecules
- Potentially toxic protein aggregates
The UPS is the primary cellular system for targeted protein degradation:
Proteasomal Degradation: HERC4 ubiquitinates proteins for 26S proteasome recognition and degradation
Regulated Signaling: Ubiquitination modulates signaling pathway activity through:
- Receptor downregulation
- Kinase regulation
- Transcription factor control
Cellular Stress Response: HERC4 participates in various stress-responsive pathways
HERC4 plays important roles in cell cycle control in neurons:
G1/S Transition: Regulates cyclin-dependent kinase inhibitors
S Phase Progression: Modulates DNA replication factors
M Phase: Affects mitotic spindle assembly and chromosome segregation
In post-mitotic neurons, these functions are repurposed for DNA damage response and cellular stress handling.
Proper ubiquitination is neuroprotective:
- Clears misfolded and aggregation-prone proteins
- Maintains synaptic protein turnover
- Regulates apoptotic pathways
- Handles cellular stress
The ubiquitin-proteasome system is severely impaired in AD :
Tau Pathology: HERC4 may be involved in tau ubiquitination and clearance:
- Tau aggregates overwhelm the UPS
- HERC4 activity may be reduced in AD brains
- Impaired tau clearance contributes to neurofibrillary tangle formation
Amyloid-beta: The UPS regulates amyloid precursor protein (APP) processing and amyloid-beta clearance:
- HERC4 may regulate APP trafficking
- UPS dysfunction contributes to amyloid accumulation
Synaptic Loss: Impaired protein degradation contributes to synaptic degeneration:
- Synaptic proteins accumulate as aggregates
- UPS dysfunction in synapses correlates with cognitive decline
Neuroinflammation: UPS dysfunction activates inflammatory pathways:
- NF-κB signaling dysregulation
- Inflammasome activation
PD is strongly linked to UPS dysfunction:
Alpha-synuclein Clearance: The UPS is critical for degrading alpha-synuclein:
- HERC4 may contribute to alpha-synuclein ubiquitination
- UPS impairment leads to Lewy body formation
Parkin Connection: PARKIN is another HECT-domain E3 ligase that is mutated in familial PD:
- Shares functional overlaps with HERC4
- Both involved in mitochondrial quality control
Dopaminergic Neuron Vulnerability: The UPS is particularly important in:
- High metabolic demand neurons
- Substantia nigra dopaminergic neurons
- Cells with high protein turnover
LRRK2 Interaction: LRRK2 mutations (PARK8) affect protein trafficking and may intersect with HERC4 function.
Amyotrophic Lateral Sclerosis (ALS): UPS dysfunction in motor neurons, TDP-43 inclusions
Huntington's Disease: Mutant huntingtin overwhelms the UPS, HERC4 may help clear aggregates
Frontotemporal Dementia: Ubiquitin-positive inclusions, TDP-43 pathology
Prion Diseases: UPS impairment in prion-infected brains
In neurodegeneration, multiple factors inhibit proteasome function:
- Oxidative damage to proteasome components
- Accumulation of ubiquitinated proteins
- Proteasome subunit oxidation
- Lipid membrane alterations
UPS dysfunction occurs through:
- Reduced E1/E2/E3 activity
- Impaired ubiquitin recycling
- Depletion of free ubiquitin pools
- Dysregulated deubiquitinating enzymes (DUBs)
Protein aggregates sequester:
- Proteasome complexes
- Ubiquitin-conjugating enzymes
- Chaperone proteins
- Essential cellular components
This creates a vicious cycle where aggregates impair their own clearance.
Oxidative damage affects:
- Enzymatic activity of UPS components
- Protein substrate recognition
- Ubiquitin conjugation efficiency
| Approach |
Strategy |
Status |
| Proteasome activators |
Increase proteasome activity |
Preclinical |
| E3 ligase modulators |
Enhance HERC4 activity |
Research |
| Ubiquitin supplementation |
Restore ubiquitin pools |
Early stage |
| DUB inhibitors |
Reduce deubiquitination |
Various |
- AAV-mediated HERC4 expression
- CRISPR approaches to enhance activity
- Small hairpin RNA to reduce toxic substrates
- Small molecules that prevent aggregation
- Chaperone-based approaches
- Autophagy induction to compensate for UPS defects
- Characterizing HERC4 substrates in neurons
- Understanding substrate specificity
- Mapping ubiquitination sites
¶ Understanding Regulation
- Post-translational modifications of HERC4
- Cellular signaling that modulates activity
- Tissue-specific expression patterns
- Patient-derived iPSC neurons
- Knockout and knock-in mouse models
- Drosophila models for rapid screening
HERC4 participates in the canonical ubiquitination pathway:
E1 Activation:
- Ubiquitin-activating enzyme activates ubiquitin in ATP-dependent manner
- Forms thioester bond between E1 catalytic cysteine and ubiquitin C-terminus
- Multiple E1 enzymes (UBA1, UBA6, UBA7) can activate ubiquitin
E2 Conjugation:
- Activated ubiquitin transferred to E2 conjugating enzyme
- E2 determines ubiquitin chain type and linkage
- HERC4 works with multiple E2 enzymes
E3 Ligation:
- HERC4 (E3) provides substrate specificity
- Catalyzes isopeptide bond formation between ubiquitin and substrate lysine
- HECT domain forms ubiquitin thioester intermediate before transfer
HERC4 can generate different ubiquitin linkages:
| Chain Type |
Function |
Neuronal Relevance |
| K48 linkage |
Proteasomal degradation |
Protein quality control |
| K63 linkage |
Signaling, autophagy |
Traffic, DNA repair |
| K27 linkage |
Protein aggregation |
Aggregate handling |
| K29 linkage |
Lysosomal degradation |
Membrane traffic |
| Monoubiquitination |
Endocytosis, signaling |
Receptor regulation |
HERC4 recognizes substrates through:
Direct Binding:
- Specific degron sequences in substrates
- Post-translational modification recognition (phosphorylation)
- Pre-formed recognition domains
Adaptor-Mediated:
- Interaction with substrate recognition co-factors
- E3 ligase complexes for specificity
- scaffolding proteins for localization
| Approach |
Strategy |
Development Status |
| Proteasome activators |
Increase 26S proteasome activity |
Preclinical |
| E3 ligase modulators |
Enhance HERC4 activity |
Research |
| Ubiquitin supplementation |
Restore cellular ubiquitin pools |
Early stage |
| Deubiquitinase inhibitors |
Reduce substrate recycling |
Various |
| Chaperone enhancement |
Help refold misfolded proteins |
Preclinical |
AAV-Mediated Expression:
- Neuronal targeting with AAV9 and AAV-PHP.B
- HERC4 wild-type delivery for loss-of-function
- Promoter selection for cell-type specificity
- Dose optimization for safety
CRISPR Approaches:
- Gene activation to boost expression
- Allele-specific editing for mutations
- Safe harbor integration for stable expression
- Guide RNA delivery optimization
Small Molecule Approaches:
- Compounds that prevent aggregate formation
- Modulators of aggregate toxicity
- Enhancers of aggregate clearance
Biological Approaches:
- Antibody-based therapies
- Peptide inhibitors
- Gene silencing for toxic protein reduction
Autophagy Induction:
- mTOR-independent activators
- TFEB overexpression
- Autophagy adaptor enhancement
Fluid Markers:
- Blood ubiquitin levels
- Proteasome activity in blood cells
- Urinary ubiquitin fragments
- CSF proteasome markers
Imaging Markers:
- PET tracers for protein aggregates
- MRI for brain atrophy patterns
- Molecular imaging of UPS function
Disease Progression:
- Baseline UPS function predicts progression
- Longitudinal monitoring of biomarkers
- Correlation with clinical endpoints
Therapeutic Monitoring:
- Target engagement biomarkers
- Proteasome activity changes
- Ubiquitin conjugate levels
Genetic Testing:
- HERC4 mutation screening
- Family history analysis
- Variant interpretation
- Predictive testing
Phenotypic Assessment:
- Disease stage determination
- Clinical presentation characterization
- Comorbidity assessment
- Treatment history
Endpoints:
- Motor function measures
- Cognitive assessments
- Biomarker changes
- Quality of life measures
Patient Selection:
- Genetic stratification
- Biomarker-based enrichment
- Disease stage optimization
- Comorbidity considerations
Registry Studies:
- Natural history of HERC4-related conditions
- Treatment outcomes in clinical practice
- Long-term safety monitoring
- Comparative effectiveness
In Vitro Models:
- Primary neuron cultures
- iPSC-derived neurons
- Neuronal cell lines
- Organoid systems
In Vivo Models:
- Transgenic mouse models
- Knockout and knock-in studies
- Viral vector delivery
- Behavioral phenotyping
Protein Analysis:
- Ubiquitin chain mapping
- Substrate identification
- Interaction network analysis
- Post-translational modification profiling
Functional Assays:
- Proteasome activity measurement
- Ubiquitination assays
- Autophagy flux monitoring
- Protein turnover studies
| Gene |
Tissue Expression |
Function |
Disease Links |
| HERC1 |
Ubiquitous |
Ribosomal quality control |
Neurodevelopmental |
| HERC2 |
High in brain |
DNA repair, mitophagy |
Rett syndrome |
| HERC3 |
High in brain |
Inflammation regulation |
Not well characterized |
| HERC4 |
Brain, testis |
Protein quality control |
AD, PD |
| HERC5 |
Immune cells |
ISGylation |
Immune disorders |
| HERC6 |
Testis |
ISGylation |
Male fertility |
HERC4 shows species-specific features:
- Human: Brain-enriched expression
- Mouse: Broader expression pattern
- Zebrafish: Developmental expression
- Drosophila: Essential for viability
- What are the specific neuronal substrates of HERC4?
- How does HERC4 activity change in neurodegenerative diseases?
- Can HERC4 be therapeutically modulated effectively?
- What determines HERC4 substrate specificity?
- How does HERC4 interact with other E3 ligases?
Amyotrophic Lateral Sclerosis (ALS):
- UPS dysfunction in motor neurons
- TDP-43 inclusions with ubiquitin
- SOD1 mutant clearance defects
- Protein aggregate accumulation
Huntington's Disease:
- Mutant huntingtin clearance defects
- Transcriptional dysregulation
- Vesicle trafficking impairment
- Mitochondrial dysfunction
Frontotemporal Dementia:
- TDP-43 proteinopathy
- Ubiquitin-positive inclusions
- Behavioral variant associations
- Language variant patterns
Prion Diseases:
- PrP^Sc accumulation
- UPS impairment in prion infection
- Synaptic dysfunction
- Neurodegeneration progression
Multiple mechanisms contribute to proteasome dysfunction:
Direct Inhibition:
- Oxidative damage to proteasome subunits
- Covalent modification by reactive species
- Aggregation of proteasome components
Indirect Inhibition:
- Substrate overload from aggregates
- Sequestration of proteasome in aggregates
- Transcriptional downregulation
Protein aggregates sequester critical components:
- 26S proteasome complex entrapment
- Hsp70 family members trapped
- Transcription factors and signaling molecules
Oxidative stress and UPS dysfunction form a vicious cycle:
- Mitochondrial dysfunction increases ROS
- Damaged proteins overwhelm UPS
- Reduced proteasome activity
| Interactor |
Interaction Type |
Functional Consequence |
| UBA1 |
E1 enzyme |
Ubiquitin activation |
| UBE2D1 |
E2 enzyme |
Ubiquitin transfer |
| UBE2E1 |
E2 enzyme |
Substrate recognition |
Chaperones:
- Hsp70 for substrate delivery
- Hsp90 for complex stabilization
- Bag family for Hsp70 regulation
Autophagy Adaptors:
- p62/SQSTM1 for selective autophagy
- NBR1 for ubiquitinated cargo
- Optineurin for autophagic clearance
Genetic Testing:
- HERC4 mutation screening
- Family history analysis
- Variant interpretation
- Predictive testing
Phenotypic Assessment:
- Disease stage determination
- Clinical presentation characterization
- Comorbidity assessment
Endpoints:
- Motor function measures
- Cognitive assessments
- Biomarker changes
- Quality of life measures
Patient Selection:
- Genetic stratification
- Biomarker-based enrichment
- Disease stage optimization
- Single-cell transcriptomics: HERC4 expression across neuronal types
- Spatial proteomics: Substrate localization mapping
- CRISPR screens: Genetic modifiers of HERC4 function
- Structural studies: HECT domain conformational changes
graph LR
A["Ubiquitin"] --> B["E1 Activation"]
B --> C["E2 Conjugation"]
C --> D["HERC4 E3 Ligation"]
D --> E["Substrate Ubiquitination"]
E --> F["Proteasome Degradation"]
E --> G["Autophagy"]
E --> H["Signaling Modulation"]
F --> I["Peptide Generation"]
G --> J["Organelle Clearance"]
H --> K["Pathway Regulation"]
I --> L["Cellular Recycling"]
J --> L
K --> L
L --> M["Cellular Homeostasis"]
| Feature |
Normal |
Disease State |
| HERC4 activity |
High |
Reduced |
| Proteasome function |
Efficient |
Impaired |
| Protein clearance |
Effective |
Reduced |
| Aggregate handling |
Normal |
Overwhelmed |
| Neuronal survival |
Maintained |
Compromised |